Fortress Biotech
FBIO
About: Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
Employees: 101
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
33% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 12
20% more capital invested
Capital invested by funds: $7.66M [Q1] → $9.23M (+$1.57M) [Q2]
11% more call options, than puts
Call options by funds: $152K | Put options by funds: $137K
7% more funds holding
Funds holding: 46 [Q1] → 49 (+3) [Q2]
1.02% less ownership
Funds ownership: 17.79% [Q1] → 16.77% (-1.02%) [Q2]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
HC Wainwright & Co.
Joseph Pantginis
|
$17
|
Buy
Maintained
|
21 Aug 2025 |
Financial journalist opinion
Based on 3 articles about FBIO published over the past 30 days
